Diagnostic lab chains like Thyrocare, Dr Lal PathLabs, SRL, and Metropolis are fundamentally changing the patient journey in India — and cutting the doctor out of the first step. When patients can walk into a diagnostic centre (or order home collection) for a "Full Body Health Package" at Rs 999-3,000 without a doctor's referral, the lab — not the doctor — becomes the first entity that holds the patient's health data. The doctor becomes the secondary interpreter of data the lab already owns. Over 60% of patients now verify their symptoms online before seeing a doctor, and an increasing number go to labs first.
The Shift: Lab Before Doctor
The Traditional Patient Journey:
- 1Patient feels unwell
- 2Visits doctor
- 3Doctor examines, recommends tests
- 4Patient goes to lab
- 5Results come back to doctor
- 6Doctor interprets and treats
The New Patient Journey:
- 1Patient feels unwell
- 2Searches symptoms online
- 3Sees "Full Body Health Package" ad
- 4Gets tests done at lab (no doctor referral)
- 5Lab provides results with "reference ranges"
- 6Patient sees doctor ONLY IF results are abnormal
The structural implication: In the new journey, the lab owns the first data point. The doctor enters the picture only after the lab has already defined the patient's "problem" through test results. The doctor's role shifts from primary investigator to secondary interpreter.
How Diagnostic Chains Make Money
Revenue Model:
Routine pathology (blood tests, urine analysis, basic panels): 40-60% margin. Specialized tests (hormone panels, tumor markers, genetic tests): 50-70% margin. Health packages (bundled test panels — full body, cardiac, diabetes): 50-65% margin. Home collection (phlebotomist visits home for sample collection): Premium pricing. Corporate wellness (employer-paid annual health checks for employees): High volume, moderate margin. B2B hospital outsourcing (processing tests for hospitals without their own labs): Bulk pricing, consistent volume.
The Package Economics:
A "Full Body Health Package" priced at Rs 999-3,000 typically includes:
- Complete Blood Count (cost: Rs 50-80)
- Lipid Panel (cost: Rs 60-100)
- Blood Sugar (cost: Rs 30-50)
- Liver Function (cost: Rs 80-120)
- Kidney Function (cost: Rs 70-100)
- Thyroid Profile (cost: Rs 100-150)
- Total actual test cost: Rs 390-600
At Rs 999 pricing, the margin is Rs 400-600 (40-60%). At Rs 2,999, the margin is Rs 2,400+ (80%+).
Why This Threatens Private Practitioners
- 1Patient Relationship Capture
When a patient gets their blood tests from Dr Lal PathLabs, the lab has their phone number, email, test history, and health data. The lab can send: reminders for repeat tests, promotional offers for additional packages, and health tips that keep the patient engaged — all without a doctor involved.
The doctor who would have ordered those tests has lost the initial patient touchpoint. If the lab results are normal, the patient may never see a doctor at all. If abnormal, the patient may search for a doctor online rather than returning to one who referred them — because no doctor referred them.
- 1Revenue Diversion
Every test a patient gets directly from a lab is a test that a doctor-referred pathway didn't generate. For doctors who earn referral income from associated labs (though technically against NMC ethics rules), the direct-to-consumer model eliminates this revenue stream entirely.
For doctors whose clinical reputation is built on thorough investigation and diagnosis, the "pre-investigated" patient who arrives with lab-ordered tests disrupts the diagnostic process — the tests ordered may not match the clinical question.
- 1Commoditization of Diagnostics
When patients compare "Rs 999 health package" prices across Thyrocare, Dr Lal, SRL, and Metropolis on aggregator platforms, diagnostics become a commodity. The cheapest package wins. This drives lab chains to optimize for volume and cost — which may not align with clinical appropriateness.
What This Means for Doctors
For private practitioners: The diagnostic chains are competing for your patient's first interaction. Your response should be to build direct patient relationships that patients value beyond test ordering — clinical reasoning, treatment decisions, ongoing care management.
For hospital-based doctors: Lab chain partnerships with hospitals create complex dynamics where the hospital outsources diagnostics for cost efficiency, but the lab captures patient data and direct-to-consumer channels.
For the healthcare system: When labs determine which tests patients take (through package design) rather than doctors (through clinical assessment), there's a risk of over-investigation (unnecessary tests in packages) and under-investigation (clinically needed tests not in the package).
Frequently Asked Questions
Are lab chains replacing doctors in India? Not replacing — but repositioning. Lab chains are becoming the first point of healthcare contact for many patients, especially for screening and wellness checks. Doctors remain essential for diagnosis, treatment, and complex clinical decisions. But the patient journey increasingly starts at the lab, not the doctor's office.
Do patients trust labs more than doctors? Not necessarily more — but differently. Patients trust labs for data (test results are perceived as "objective") and convenience (walk-in access, home collection, transparent pricing). They trust doctors for interpretation and treatment decisions. The challenge for doctors is that lab data without clinical context can be misleading.
How do diagnostic chains affect doctor income? Direct-to-consumer lab tests reduce doctor-referred test volume. For doctors with lab referral arrangements (technically against NMC rules), the revenue impact is direct. For all doctors, the shift means patients arrive pre-investigated rather than seeking investigation — changing the consultation dynamic and potentially reducing the perceived value of the doctor visit.
Should doctors partner with diagnostic chains or compete? Both are viable strategies. Partnering (through practice-based collection points or digital referral agreements) maintains some control over the testing process. Competing (through in-house point-of-care testing for common investigations) keeps the diagnostic revenue within the practice. The worst option: ignoring the trend.
futurise. builds premium healthcare brands in 48 hours. Learn more at futurise.studio